|Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA||Chief Financial Officer||944.76k||N/A||1969|
|Mr. Christophe Bourdon M.B.A.||Chief Exec. Officer||N/A||N/A||1970|
|Dr. Thomas Kirkegaard Jensen Ph.D.||Co-Founder & Chief Scientific Officer||N/A||N/A||1977|
|Ms. Molly Poarch||Head of Global Communications||N/A||N/A||N/A|
|Dr. Thomas Blaettler||Chief Medical Officer||N/A||N/A||1967|
|Ms. Molly Painter||Pres of US Orphazyme||N/A||N/A||N/A|
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Orphazyme A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.